Elidel Sales Fall In Q3 On Fewer U.S. Prescriptions, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Novartis' eczema treatment Elidel (pimecrolimus) fell 36% to $53 mil. in the third quarter on fewer U.S. prescriptions, Novartis reported Oct. 18